New hope for tough blood cancers? early trial launches

NCT ID NCT07572006

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental drug called JNJ-95804306 in people with blood cancers like leukemia that have come back or not responded to standard treatments. The study has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors when used alone or with standard care. About 280 participants will take part across multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-95804306
What this could lead to: If successful, this could point toward a new treatment option for people with blood cancers that have not responded to other therapies.
What could go wrong: This is an early Phase 1 trial, so the drug may not be effective or may cause serious side effects. It is also small and focused on safety, not proof of benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell chronic lymphocytic leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC NEOPLASMS

Contacts and locations

Locations

Indiana Blood & Marrow Transplantation
RECRUITING

Indianapolis, Indiana, 46237, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, 3000, Australia
Rutgers Cancer Institute of New Jersey
RECRUITING

Piscataway, New Jersey, 08854, United States
Sarah Cannon Cancer Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Start Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
The Christie Nhs Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
UZ Antwerpen
RECRUITING

Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.